AB062. P-33. Efficacy and safety of varlitinib a reversible pan-HER tyrosine kinase inhibitor in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase 1 studies

摘要

BackgroundVarlitinib is a nanomolar inhibitor of EGFR, HER2, and HER4 and has shown potent anti-tumor activity as monotherapy in preclinical BTC models. During phase (Ph) 1 development, significant tumor shrinkage was observed in biliary tract cancer (BTC) patients (pts). Tissue microarray analysis has revealed that ~70% of BTC pts exhibit HER overexpression, suggesting varlitinib could be beneficial in BTC.